Drugs / MYL-1402O
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02469987 | Apr → Oct 2015 | — | Mylan Inc. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04633564 | Jan 2017 → Jun 2019 | non-small cell lung carcinoma | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-25 | Biocon Biologics UK Ltd | Regulatory Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020 bioconbiologics.com ↗
To complete the application, the Agency noted that an inspection of the manufacturing facility is required as a part of the standard review process. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-25 | Biocon Biologics UK Ltd | Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020 bioconbiologics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYL-1402O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633564 ↗ |
| Known as | Bevacizumab | “Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV” NCT04633564 ↗ |
| Modality | Monoclonal antibody | “MYL-1402O is a monoclonal antibody” NCT04633564 ↗ |
| Route | Intravenous | “MYL-1402O 15 mg/kg IV” NCT04633564 ↗ |